MT-act is a CNRS spin-off. #techtransfer
We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the skeleton of the cells called microtubules - abbreviated MT. Stiffening of the skeleton of our cells is a central disease driver. That is why we act on them.
We developed a technology platform to charter an entirely neglected pharmaceutical space.
MT-act prioritizes indications based on scientific evidence, proven unmet medical needs and where the roadmap to patients is feasible and desired.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Cnrs, Montpellier,occitanie 34000,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- mt-act.com
- Keywords
- Drug development, Microtubules, Tubulin code, Preclinical, Drug screening, first-in-class, drug discovery.
- HQ
- Montpellier, Occitanie
Mt-Act Questions
Mt-Act's website is mt-act.com
Mt-Act's LinkedIn profile is https://fr.linkedin.com/company/mt-act
Mt-Act has
7 employees.
View email and phone details for 7
employees at Mt-Act.
Mt-Act's industry is
Biotechnology Research
Mt-Act's top competitors are
Stem Genomics,
Phost'in Therapeutics,
Mycea,
Azelead,
Mabqi,
Insybio,
Sensorion,
Cilcare,
Acobiom,
Seqone.
Mt-Act's categories are Biotechnology Research
Mt-Act's founding year is 2019
